创伤凝血病中三因子与四因子凝血酶原复合物比较:四因子优于三因子
本研究为单中心回顾性综述,纳入2013-2017年一家一级创伤中心接受三因子或四因子凝血酶原复合物(PCC)的创伤凝血病患者,经倾向性评分1:1匹配后四因子组与三因子组各125例。四因子PCC组INR纠正时间更短(365 vs 428分钟,P=0.01),红细胞输注量更少(7 vs 10单位,P=0.04),新鲜冰冻血浆输注量更少(6 vs 8单位,P=0.03)。两组血小板输注、血栓栓塞并发症、死亡率、住院时间和ICU住院时间无差异。四因子PCC治疗费用更高但输血费用更低,总住院费用两组无差异。作者认为四因子PCC可作为创伤凝血病患者复苏的辅助治疗优先选择。
要点
- 匹配后四因子PCC组INR纠正时间365分钟,短于三因子PCC组的428分钟(P=0.01)。
- 四因子PCC组红细胞输注7单位,少于三因子PCC组的10单位(P=0.04)。
- 四因子PCC组新鲜冰冻血浆输注6单位,少于三因子PCC组的8单位(P=0.03)。
- 两组血小板输注、血栓栓塞并发症、死亡率、住院时间和ICU住院时间无差异。
- 四因子PCC治疗费用更高但输血费用更低,两组总住院费用无差异。
适用人群与场景
- 2013-2017年一家一级创伤中心接受三因子或四因子PCC的创伤凝血病患者。
- 纳入标准:符合创伤凝血病并接受三因子或四因子PCC治疗的患者,共657例符合纳入标准,其中250例(四因子PCC组125例、三因子PCC组125例)经倾向性评分1:1匹配。
处置流程与药物剂量
- 四因子PCC或三因子PCC作为创伤凝血病患者复苏的辅助治疗,具体剂量原文未报告。
研究设计与关键结果
- 研究类型:为期5年(2013-2017年)的回顾性综述,单中心一级创伤中心,纳入657例符合标准的创伤凝血病患者,经倾向性评分1:1匹配后四因子PCC组125例与三因子PCC组125例。
- 匹配后人群平均年龄50±19.4岁,男性64%,中位损伤严重度评分24[15-33]。
- 主要终点:四因子PCC组INR纠正时间365分钟 vs 三因子PCC组428分钟(P=0.01);四因子PCC组红细胞输注7单位 vs 三因子PCC组10单位(P=0.04);四因子PCC组新鲜冰冻血浆输注6单位 vs 三因子PCC组8单位(P=0.03)。
- 血小板输注、血栓栓塞并发症、死亡率、住院时间和ICU住院时间两组无差异。
- 四因子PCC组PCC治疗费用更高、输血费用更低,两组总住院费用无差异。
证据类型、等级与局限
- 证据类型:单中心回顾性综述,采用倾向性评分1:1匹配。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,与三因子PCC相比,四因子PCC与更快的INR纠正和更低的输血需求相关,且不增加总住院费用或血栓栓塞事件风险;四因子PCC可作为创伤凝血病患者复苏的辅助治疗优先选择。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Coagulopathy of trauma (COT) is common and highly lethal. Prothrombin complex concentrate (PCC) has been advocated for correction of COT. However, the difference in efficacy between three-factor PCC (3-PCC) versus four-factor PCC (4-PCC) remains unclear. The aim of our study was to compare efficacy of 3-PCC versus 4-PCC in COT.
METHODS: Five-year (2013-2017) review of coagulopathic trauma patients at our Level-I trauma center who received 3- or 4-PCC. Patients were divided into two groups (4-PCC and 3-PCC) and matched in 1:1 ratio using propensity-score-matching for demographics, injury parameters, admission vitals, and hematological parameters. Primary outcomes were time to correction of international normalized ratio (INR), blood products transfusion, thromboembolic complications, and mortality. Secondary outcomes were hospital-length of stay (LOS), intensive care unit (ICU)-LOS, cost of therapy, and total hospital cost.
RESULTS: Six hundred fifty-seven patients met inclusion criteria of whom 250 patients (4-PCC:125; 3-PCC:125) were matched. The mean age was 50 ± 19.4 y, 64% were male, and median-injury severity score was 24[15-33]. 4-PCC was associated with accelerated correction of INR (365 vs. 428 min, P = 0.01), decrease in red blood cells (7 units vs. 10 units, P = 0.04) and FFP (6 units vs. 8 units, P = 0.03) transfused. There was no difference in platelet transfusion, thromboembolic complications, mortality, hospital, and ICU-LOS. 4-PCC was associated with higher cost of PCC therapy, and lower cost of transfusion. There was no difference regarding the total hospital cost between the two groups.
CONCLUSION: Compared with 3-factor PCC, the use of 4-factor PCC is associated with a rapid reversal of INR and reduction in transfusion requirement without increasing the overall hospital cost or the risk of thromboembolic events. 4-PCC may be preferred as an adjunct for the resuscitation of coagulopathic trauma patients.
参考来源
- Zeeshan M, Hamidi M, Kulvatunyou N, et al. 3-Factor Versus 4-Factor PCC in Coagulopathy of Trauma: Four is Better Than Three. Shock. 2019. PMID: 30074978. doi:10.1097/SHK.0000000000001240
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。